Pharming Group N.V. (Euronext: PHARM; "Pharming" or "the Company") announced today that the United States Army ("US Army") will evaluate Pharming’s recombinant human fibrinogen ("rhFIB") product. The US Army will conduct studies using rhFIB to determine its use for various applications.

Based on the outcome of these studies, Pharming will supply rhFIB to the US Army for tissue sealant as well as novel therapeutic applications. The two parties will execute a Cooperative Research and Development Agreement, which will define the extent of the collaboration upon successful evaluation of rhFIB.

"We are pleased with the interest of the US Army to evaluate our recombinant human fibrinogen." said Samir Singh, Vice President and Managing Director, US. "With the recent PPL transaction, we are in a strong position to further develop our rhFIB and recombinant tissue sealant products for the significant surgical market."

Recently, Pharming acquired patents and licenses for the production and purification of recombinant human fibrinogen as well as recombinant tissue sealant compositions from PPL. In addition, the Company also obtained access to processes and know-how for the large scale GMP-grade purification of recombinant human fibrinogen.